<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511705</url>
  </required_header>
  <id_info>
    <org_study_id>3873/06-07</org_study_id>
    <nct_id>NCT01511705</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fasting Condition</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Ondansetron Hydrochloride Tablets 8 mg With Zofran® (Containing Ondansetron Hydrochloride Dihydrate) Tablets 8 mg in Healthy, Adult, Human Subjects Under Fasting Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, balanced, randomized, two-treatment, two-period, two sequence,single&#xD;
      dose, crossover, oral bioequivalence study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was an open label, balanced, randomized, two-treatment, two-period, two&#xD;
      sequence,single dose, crossover, oral bioequivalence study of Ondansetron Hydrochloride&#xD;
      tablets 8 mg of Dr. Reddy's Laboratories Limited, India comparing with that of Zofran®&#xD;
      (containing Ondansetron Hydrochloride Dihydrate) tablets 8 mg of GlaxoSmithKline, USA in&#xD;
      healthy, adult, human subjects under fasting condition. 26 subjects are enrolled in the&#xD;
      study, and 24 subjects are completed the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area unde curve (AUC)</measure>
    <time_frame>First one was within 1 hour prior to drug administration (0.0) and others at 0.33,0.67,1,1.33, 1.67, 2, 2.5, 3, 3.5,4,6,9,12,15,18 and 24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ondansetron Hydrochloride Tablets 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zofran Tablets 8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zofran Tablets 8 mg of GlaxoSmithKline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron Hydrochloride</intervention_name>
    <description>Ondansetron Hydrochloride Tablets 8 mg</description>
    <arm_group_label>Ondansetron Hydrochloride Tablets 8 mg</arm_group_label>
    <other_name>Ondansetron Hydrochloride 8 mg (Dr. Reddy's Laboratories)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron Hydrochloride</intervention_name>
    <description>Zofran Tablets 8 mg</description>
    <arm_group_label>Zofran Tablets 8 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who provide written informed consent.&#xD;
&#xD;
          -  Subjects who were healthy adults within 18 and 45 years of age (both inclusive).&#xD;
&#xD;
          -  Body mass index of ≥ 18 kg/m2 and ≤ 25 kg/m2, with body weight not less than 50 kg.&#xD;
&#xD;
          -  Subjects who had normal health as determined by medical history and physical&#xD;
             examination performed within 15 days prior to the dosing of period I.&#xD;
&#xD;
          -  Had normal ECG, Chest X-ray and vital signs&#xD;
&#xD;
          -  Availability of subjects for the entire study period and willingness to adhere to&#xD;
             protocol requirements as evidenced by written informed consent.&#xD;
&#xD;
          -  If subject is a female volunteer and is of child bearing potential practicing an&#xD;
             acceptable method of birth control for the duration of the study as judged by the&#xD;
             investigator(s),such as condoms, foams, jellies, diaphragm, intrauterine device(IUD),&#xD;
             or abstinence.&#xD;
&#xD;
        or&#xD;
&#xD;
          -  is postmenopausal for at least 1 year or&#xD;
&#xD;
          -  is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy has been performed on the subject)&#xD;
&#xD;
          -  Each female subject were supposed to undergo a urine pregnancy test to check-in for&#xD;
             period-I, period-II and post study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects incapable of understanding the informed consent.&#xD;
&#xD;
          -  Subjects BP ≤ 9060 mm/Hg or BP ≥ 140/90 mm/Hg.&#xD;
&#xD;
          -  History of hypersensitivity or idiosyncratic reaction to ondansetron or any other&#xD;
             related drugs.&#xD;
&#xD;
          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal&#xD;
             function. Subjects with a history of tuberculosis, epilepsy, asthma(during past 5&#xD;
             years), diabetes, psychosis or glaucoma were not eligible for the study.&#xD;
&#xD;
          -  Regular smoker who smokes more than ten cigarettes daily and has difficulty in&#xD;
             abstaining from smoking for the duration of each study period.&#xD;
&#xD;
          -  Subjects who has taken over the counter or prescribed medications, including any&#xD;
             enzyme modifying drugs or any systemic medication with the past 30 days prior to&#xD;
             dosing in Period-I.&#xD;
&#xD;
          -  History of any psychiatric illness, which may impair the ability to provide written&#xD;
             informed consent.&#xD;
&#xD;
          -  Subjects who have a history of alcohol or substance abuse within the last 5 years.&#xD;
&#xD;
          -  Subjects with clinically significant abnormal values of laboratory parameters.&#xD;
&#xD;
          -  Subjects who have participated in any other clinical investigation using experimental&#xD;
             drug or had bled more than 350 mL in the past 3 months.&#xD;
&#xD;
          -  Subjects who are unable to or likely to be non-complaint with protocol requirements or&#xD;
             restrictions.&#xD;
&#xD;
          -  Any subject in whom ondansetron is contraindicated for medical reasons.&#xD;
&#xD;
          -  Subjects who are intolerant to venipuncture.&#xD;
&#xD;
          -  Subjects with positive urine screen for drugs of abuse. All subjects urine samples&#xD;
             assayed for the presence of drugs of abuse at each study period check-in. Subjects who&#xD;
             found to have urine concentrations of any of the tested drugs were not allowed to&#xD;
             participate.&#xD;
&#xD;
          -  Female volunteers who has used implanted or injected hormonal contraceptives anytime&#xD;
             during the 6 months prior to study or used hormonal contraceptives with 14 days before&#xD;
             dosing.&#xD;
&#xD;
          -  Female volunteers who are not negative in pregnancy test&#xD;
&#xD;
          -  All female subjects were to be screened for pregnancy at check in of each study&#xD;
             period. Subjects with positive or inconclusive results were to be withdrawn from the&#xD;
             study.&#xD;
&#xD;
          -  Female volunteers who are currently breast feeding.&#xD;
&#xD;
          -  Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant&#xD;
             during the study were not to be allowed to participate. Female subjects of child&#xD;
             bearing potential must either abstain form sexual intercourse or use a reliable&#xD;
             barrier method (e.g condom, IUD) or contraception during the course of the study&#xD;
             (first dosing until last blood collection) or they were not to be allowed to&#xD;
             participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. I.S Gandhi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vimta Labs Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vimta Labs Limited</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 051</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

